Orakl Oncology has raised a $34 million Series A co-led by Norrsken and Singular, Sifted reported on November 12. The Paris startup builds tumor models meant to show how cancer drugs may perform before they enter human trials.
Orakl grows tumor organoids from patient samples, screens them against drugs and matches the results with molecular measurements and clinical histories. It markets that combination, including a product called O-Predict, to biopharma partners that need help choosing trial patients and treatment combinations.
Singular also led Orakl’s December 2024 seed round, which was meant to launch two commercial products, O-Predict and O-Validate. At the time Orakl also planned to use the platform to choose programs to license and build an internal pipeline, Tech.eu reported.
On July 15, Orakl said it had secured exclusive rights to four Sanofi oncology assets through two agreements and would use O-Predict to estimate clinical responses and pick a development path for each program. The announcement did not name the drugs or their stages, and it does not establish that the new round is earmarked for those assets.